Showing 8311-8320 of 8879 results for "".
- Topix Pharmaceuticals Introduces All-Trans-Retinol Smoothing Body Lotionhttps://practicaldermatology.com/news/topix-pharmaceuticals-introduces-all-trans-retinol-smoothing-body-lotion/2458439/Topix Pharmaceuticals, Inc. has introduced All-trans-Retinol Smoothing Body Lotion, a retinol body treatment featuring layered ingredient technologies and a powerful delivery system for ultimate penetration. Replenix Smoothing Body Lotion contains the maximum dosage of retinol to be safe
- Cloudy with a Chance of Wrinkles: ROC Ranks US Cities By Wrinkle Indexhttps://practicaldermatology.com/news/cloudy-with-a-chance-of-wrinkles-roc-ranks-cities-by-wrinkle-index/2458453/Philadelphia will be the most wrinkle-prone city in America come 2040 thanks to high stress levels, more airborne pollution, lengthy commute times and higher than average smoking rates, according to the 2016 RoC® Wrinkle Ranking. San Jose, Calif. will hold the least wrinkle-pron
- Freedom Laser Therapy Launches iRESTORE Hair Growth Systemhttps://practicaldermatology.com/news/freedom-laser-therapy-launches-irestore-hair-growth-system/2458457/Freedom Laser Therapy is rolling out the iRestore Hair Growth System. The hands-free iRestore Hair Growth System is US Food and Drug Administr
- Deadline Approaching: Apply for Grant from La Roche-Posay's "Dermatologist from the Heart" Programhttps://practicaldermatology.com/news/deadline-approaching-apply-for-grant-from-la-roche-posays-dermatologist-from-the-heart-program/2458476/La Roche-Posay plans to continue its "Dermatologist from the Heart" program for the fifth year. As part of the program, La Roche-Posay provides grant money up to $10,000 to fund community-oriented projects that ma
- UofL Dermatology Chief Tapped by ACCMEhttps://practicaldermatology.com/news/uofl-dermatology-chief-tapped-by-accme/2458477/Jeffrey P. Callen, MD, chief of the Division of Dermatology at the University of Louisville School of Medicine in Kentucky, has been elected to serve on the Accreditation Review Committee (ARC) of the Accreditation Council of Continuing Medical Education (ACCME).
- Almirall, Sun Pharma Enter into a License Agreement for Psoriasis Drug Tildrakizumab in Europehttps://practicaldermatology.com/news/almirall-sun-pharma-enter-into-a-license-agreement-for-psoriasis-drug-tildrakizumab-in-europe/2458485/Sun Pharmaceutical Industries Ltd and Almirall will work together to develop and commercialize tildrakizumab for psoriasis in Europe. Tildrakizumab is an investigational IL-23p19 inhibitor currently being e
- FDA Cracks Down on Mercury in Anti-Aging Productshttps://practicaldermatology.com/news/fda-cracks-down-on-mercury-in-anti-aging-products/2458488/The U.S. Food and Drug Administration is re-issuing a warning about the dangers of mercury in skin creams, beauty and antiseptic soaps, and lotions. In the past few years, the FDA and state health officials
- FDA Advisory Arm Recommends Brodalumab For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-advisory-arm-recommends-brodalumab-for-moderate-to-severe-plaque-psoriasis/2458497/A US. Food and Drug Administration (FDA) advisory panel voted to greenlight Valeant’s IL-17 blocker brodalumab for the treatment of moderate-to-severe plaque psoriasis in adults. The committee voted 18 to 0 in favor of brodalumab injection, 210
- Revance's Injectable Toxin to Enter Phase 3 Trialshttps://practicaldermatology.com/news/revances-injectable-toxin-to-enter-phase-3-trials/2458500/It’s game on for Revance Therapeutics, Inc. The company expects to initiate Phase 3 clinical trials of Injectable DaxibotulinumtoxinA (RT002) for the treatment of glabellar lines in the second half of 2016. Revance is moving forward with an
- FDA Advisory Committee Votes to Approve Biosimilar Etanercept from Sandozhttps://practicaldermatology.com/news/fda-advisory-committee-votes-to-approve-biosimilar-etanercept-from-sandoz/2458502/The US FDA Arthritis Advisory Committee recommended approval of Sandoz's proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five indications of the reference product, including rheumatoid arthritis (RA), plaque psoriasis (PsO),